CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Auscann Group Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Auscann Group Holdings Ltd
Wangara
PO Box 1746
Phone: +61 863050705p:+61 863050705 PERTH, WAS  6947  Australia Fax: +61 399097585f:+61 399097585
This company is no longer actively traded on any major stock exchange.
Business Summary
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. It has launched tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on the Company’s Neuvis platform, for the treatment of pain and related indications. Its products include CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board AndrewChapman 43 12/1/2023 12/1/2023
Chief Financial Officer, Company Secretary ChristopherMews 5/16/2024 12/1/2019
Head of Research and Development MargaretCurtis 3/18/2021 3/18/2021
Non-Executive Director Piers R.Lewis 6/11/2024 6/11/2024
Non-Executive Independent Director RobertClifford

Subsidiaries
Business Name Address City State/Province Country
CannPal Animal Therapeutics Ltd. L 3 45a Bay Street, Double Bay Sydney NSW Australia

Business Names
Business Name
Australian Commercial Wines Pty Ltd
Cannpal Animal Therapeutics Ltd
Cockatoo Ridge Wines Ltd

General Information
Number of Employees: 27 (As of 6/30/2006)
Outstanding Shares: 440,547,110 (As of 12/31/2023)
Shareholders: 15,023
Stock Exchange: ASX
Fax Number: +61 399097585


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024